| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
Whether circulating tumor cells(CTC) could be a prediction factor of the postoperative recurrence of lung cancer was investigated. Also CTC was utilized to establish order-made adjuvant chemotherapy. EpCAM、anti-cytokeratin mAb with magnetic beads were used to isolate CTC. Sensitivity of the method was raised to detect 1/100000 of PC9 tumor cells among normal leucocyte. CTC was examined in blood samples of advanced stage of lung cancer as well as post-operative patients. CTC was detected in 3% in advanced stage while no positive case in post-operative patients. The present condition is under re-examination for improvement in its sensitivity. ERCC gene family, beta-Tubulin, and RRM1 using Allele specific PCR and Real time PCR are under examination.
|
